Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of Brivekimig, a Dual Anti-TNF-α and Anti-OX40L NANOBODY® Molecule, for Preservation of Pancreatic β-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes

NCT06812988 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06812988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06812988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of Brivekimig, a Dual Anti-TNF-α and Anti-OX40L NANOBODY® Molecule, for Preservation of Pancreatic β-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 28, 2025
Completion date
April 29, 2027
Enrollment
84 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus